secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2024-05-03T23:59:59+00:00
Accession:  0001372514-24-000039
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora shareholders approve reverse stock split and increase authorized shares to 150M
--------------------------------------------------------------------------------

- Reverse stock split of common stock approved at a ratio between 1-for-2 and 1-for-10; board will set exact ratio and timing.
- Authorized common shares increased to 150,000,000 total authorized shares of all classes to 160,000,000 (including 10M preferred).
- Issuance of up to 49,374,590 common shares upon exercise of Tranche A and B Warrants from February 2024 private placement approved.
- Proposal to adjust voting requirements for certain future amendments failed to pass.
- David Hollander, MD, MBA and Erin Parsons elected as Class III directors for a three-year term ending at 2027 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000039/0001372514-24-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000039/kprx-20240501.htm
  HTML page:      https://secwatch.observer/filing/0001372514-24-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer